NEWPORT BEACH, Calif.—BioCell Technology announced that new findings from a pilot, placebo-controlled, human clinical trial on BioCell Collagen will be presented during the International Society of Sports Nutrition (ISSN) Conference in Clearwater Beach, Florida, June 20-21.
Tim Ziegenfuss, Ph.D., FISSN, co-founder and chief scientific officer of The Center for Applied Health Sciences, will discuss the data during a speaker presentation at 3:30 p.m. on June 20. Lead investigator on the study, Hector Lopez, M.D., a board certified doctor in physical medicine and rehabilitation, will lead a poster presentation session on June 21 at 1 p.m.
"This new clinical study in physically active healthy subjects provides intriguing new data suggesting that this patented, scientifically substantiated dietary supplement has promising new applications in sports nutrition," said Joosang Park, Ph.D., vice president of scientific affairs at BioCell Technology.
BioCell Collagen is a patented, science-based clinically substantiated dietary ingredient that promotes active joints, youthful looking skin and healthy connective tissues. It contains a patented composition of naturally occurring hydrolyzed collagen type II, chondroitin sulfate and hyaluronic acid in a highly absorbable matrix form that has been the subject of human clinical trials for safety, efficacy and bioavailability. BioCell Technology researches, develops, brands and distributes science-based raw material ingredients that have applications in health and beauty.